Gillessen S, Pluetschow A, Vucinic V, Ostermann H, et al. JAK Inhibition with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: Final Results of A Phase II, Open Label, Multicenter Clinical Trial (JeRiCHO). Eur J Haematol 2022 Sep 3. doi: 10.1111/ejh.13859.
PMID: 36056778